BIOX vs ICL
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 23, 2026
BIOX
ICL
Investment Advisor Scores
ICL
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BIOX | ICL | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 14.9925 | 55.5556 | BIOX |
| PEG Ratio | 1.9521 | 9.44 | BIOX |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | -23.4% | 16.5% | ICL |
| Earnings Growth | 34.4% | 51.6% | ICL |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 41.0/100 | 39.2/100 | BIOX |
| Profit Margin | -19.7% | 4.0% | ICL |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | AVOID NEW MONEY | BIOX |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BIOX
MarkdownPrice below a falling SMA50 (slope -4.6%), weak momentum, RSI 21
ICL
MarkdownPrice below a falling SMA50 (slope -1.9%), weak momentum, RSI 32
Fundamentals Snapshot
| Metric | BIOX | ICL |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 4.7 | 11.0 |
| Trailing P/E | — | 19.6 |
| Revenue (TTM) | — | — |
| Revenue Growth | -0.2% | 0.2% |
| Gross Margin | 0.3% | 0.3% |
| Operating Margin | -0.2% | 0.1% |
| EPS | -0.75 | 0.24 |
| Dividend Yield | — | 0.04% |